The Scripps Research Institute Adopts MDL Informatics Applications to Support Research for NIH Program

The Scripps Research Institute has selected a package ofinformatics applications from Elsevier MDL to power its researchefforts as one of nine institutions chosen to participate in theNational Institutes of Health (NIH) Molecular Libraries ScreeningCenters Network (MLSCN). Researchers at the Palm Beach County, Floridacampus of The Scripps Research Institute will use MDL applications tosupport high-throughput molecular screening as part of a nationwidecollaborative project aimed at accelerating medical discovery.

The Scripps Research Institute will use high-throughput andhigh-content screening techniques to evaluate small molecules againstvarious biological targets for suitability in developing newtreatments for human diseases. While screening and evaluatingpharmacokinetic and toxicological properties, Scripps researchers willutilize a suite of MDL applications, including MDL(R) AssayExplorer(R) biological data management system, MDL(R) ChemBioregistration system and MDL(R) Plate Manager sample and platemanagement system to capture and analyze the flood of data that comesfrom those studies.

"Our goal is to identify molecular entities or molecular classesthat may have potential benefit for the development of therapeutics bythe private sector," said Nick Tsinoremas, Senior Director ofInformatics and co-principal investigator for the Scripps Floridascreening center. "MDL applications give us a full range of proveninformatics capabilities to manage the complex screening we'll employin this research."

Elsevier MDL, the leading informatics, database and workflowsolution provider for life sciences R&D, offers flexible MDL Selectpackages of attractively priced informatics and experiment managementtools that enable smaller or start-up biopharma companies to manageentire discovery workflows using the same scalable discovery solutionsemployed by global organizations.

"The suite of MDL applications, selected by Scripps Institute willenable scientists to capture biological and chemical information andintegrate it to visualize, analyze and report on experimental data inan advanced collaborative environment," said Jean Colombel, SeniorVice President, Sales and Services, Elsevier MDL. "We're pleased thatElsevier MDL is the principal partner in research informatics for theScripps Institute Molecular Screening Center and that MDL technologywill contribute to the important efforts of the Molecular LibraryScreening Network."

The MLSCN is part of the NIH Roadmap, a series of initiativesdesigned to pursue biomedical research and catalyze changes that willtransform new scientific knowledge into tangible benefits for publichealth. The Scripps Research Institute Screening Center is funded by agrant from the NIH. Information generated by the screening centerswill be made available to the public through a database maintained bythe National Library of Medicine at NIH.

For more information on MDL applications, visit www.mdl.com. Tolearn about The Scripps Research Institute, visit www.scripps.edu.

About Elsevier MDL

Elsevier MDL provides informatics, database and workflow solutionsthat accelerate successful life sciences R&D by improving the speedand quality of scientists' decision making. Researchers around theworld depend on Elsevier MDL for innovative and reliable discoveryinformatics software solutions and services augmented by 400 Elsevierchemistry and life sciences journals and related products. For moreinformation, visit www.mdl.com. Elsevier is a world-leading publisherof scientific, technical and medical information products andservices. For more information, visit www.elsevier.com.

Elsevier is part of Reed Elsevier Group plc, a world-leadingpublisher and information provider. Reed Elsevier's ticker symbols areREN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL(New York Stock Exchange). For more information, visitwww.reedelsevier.com.

About The Scripps Research Institute

The Scripps Research Institute, headquartered in La Jolla,California, is one of the world's largest independent, non-profitbiomedical research organizations. It stands at the forefront of basicbiomedical science that seeks to comprehend the most fundamentalprocesses of life. Scripps Research is internationally recognized forits research into immunology, molecular and cellular biology,chemistry, neurosciences, autoimmune, cardiovascular, and infectiousdiseases, and synthetic vaccine development. Established in itscurrent configuration in 1961, it employs approximately 3,000scientists, postdoctoral fellows, scientific and other technicians,doctoral degree graduate students, and administrative and technicalsupport personnel.

Scripps Florida, a 364,000 square-foot, state-of-the-artbiomedical research facility, is to be built in Palm Beach County. Thefacility will focus on basic biomedical science, drug discovery, andtechnology development. Palm Beach County and the State of Floridahave provided start-up economic packages for development, building,staffing, and equipping the campus. Scripps Florida now operates withapproximately 150 scientists, technicians, and administrative staff at40,000 square-foot lab facilities on the Florida Atlantic Universitycampus in Jupiter.

MDL and Assay Explorer are registered trademarks of MDLInformation Systems, Inc. ('Elsevier MDL') in the United States. Allrights reserved. All other trademarks mentioned in this document arethe property of their respective owners.